BACKGROUND. Severe plaque-type psoriasis has been successfully treated with orally administered cyclosporine, but there has been no comparative, controlled evaluation of various dosages and their efficacy and side effects. METHODS. In a 16-week, double-blind trial, we randomly assigned 85 patients with severe psoriasis to receive 3, 5, or 7.5 mg of cyclosporine per kilogram of body weight per day or a placebo consisting of the vehicle for the drug. After eight weeks the dose could be adjusted to improve safety or efficacy while maintaining blinding. RESULTS. The psoriasis improved in a dose-dependent fashion. After eight weeks of fixed-dose therapy, 36, 65, and 80 percent of the patients receiving 3, 5, and 7.5 mg of cyclosporine per kilogram per day, respectively, were rated as being clear or almost clear of psoriasis; each group had significant improvement (P less than 0.0001) as compared with the group receiving vehicle, in which none of the patients were rated as clear or almost clear. The patients who received 5 mg per kilogram were the least likely to require dosage adjustments because of side effects or a lack of efficacy. The glomerular filtration rate, measured in a subgroup of 34 patients receiving cyclosporine, decreased by a median of 16 percent. Higher doses of cyclosporine had greater adverse effects on systolic blood pressure, glomerular filtration rate, and serum levels of creatinine, uric acid, bilirubin, and cholesterol. Delayed-type hypersensitivity reactions to skin-test antigens were reduced by cyclosporine administration. Cyclosporine appears to become concentrated in skin. CONCLUSIONS. Cyclosporine therapy leads to a rapid and thorough clearing of psoriasis; an initial dose of 5 mg per kilogram per day seems to be appropriate. However, the safety of cyclosporine for the long-term treatment of psoriasis remains to be determined.
Source Information
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109-0314.
This article has been cited by other articles:
Goodman, W. A., Levine, A. D., Massari, J. V., Sugiyama, H., McCormick, T. S., Cooper, K. D.
(2009). IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. J. Immunol.
183: 3170-3176
[Abstract][Full Text]
ALTOMARE, G. F., ALTOMARE, A., PIGATTO, P. D.
(2009). Traditional Systemic Treatment of Psoriasis. The Journal of Rheumatology Supplement
83: 46-48
[Abstract][Full Text]
Gisondi, P., Del Giglio, M., Di Francesco, V., Zamboni, M., Girolomoni, G.
(2008). Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr.
88: 1242-1247
[Abstract][Full Text]
Weatherhead, S., Robson, S. C, Reynolds, N. J
(2007). Management of psoriasis in pregnancy. BMJ
334: 1218-1220
[Full Text]
Cumberbatch, M., Singh, M., Dearman, R. J., Young, H. S., Kimber, I., Griffiths, C. E.M.
(2006). Impaired Langerhans cell migration in psoriasis. JEM
203: 953-960
[Abstract][Full Text]
Spuls, P. I., Witkamp, L., Bossuyt, P. M. M., Bos, J. D.
(2004). The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies. Arch Dermatol
140: 338-344
[Abstract][Full Text]
Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., Griffiths, C. E. M.
(2003). An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis. Arch Dermatol
139: 719-727
[Abstract][Full Text]
Gottlieb, A B
(2003). Clinical research helps elucidate the role of tumor necrosis factor-{alpha}in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus
12: 190-194
[Abstract]
Kimball, A. B., Kawamura, T., Tejura, K., Boss, C., Hancox, A. R., Vogel, J. C., Steinberg, S. M., Turner, M. L., Blauvelt, A.
(2002). Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10. Arch Dermatol
138: 1341-1346
[Abstract][Full Text]
Mease, P J
(2002). Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis
61: 298-304
[Abstract][Full Text]
Van den Bosch, F, Baeten, D, Kruithof, E, De Keyser, F, Mielants, H, Veys, E M
(2001). Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis
60: iii33-36
[Full Text]
Mease, P J
(2001). Cytokine blockers in psoriatic arthritis. Ann Rheum Dis
60: iii37-40
[Abstract][Full Text]
Ellis, C. N., Krueger, G. G., the Alefacept Clinical Study Group,
(2001). Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes. NEJM
345: 248-255
[Abstract][Full Text]
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., Krueger, J. G.
(2000). Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells. JEM
192: 681-694
[Abstract][Full Text]
Robert, C., Kupper, T. S.
(1999). Inflammatory Skin Diseases, T Cells, and Immune Surveillance. NEJM
341: 1817-1828
[Full Text]
Murphy, F. P., Coven, T. R., Burack, L. H., Gilleaudeau, P., Cardinale, I., Auerbach, R., Krueger, J. G.
(1999). Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis: Evidence for Selective Effects on Activated T Lymphocytes. Arch Dermatol
135: 1495-1502
[Abstract][Full Text]
Ballow, M., Nelson, R.
(1997). Immunopharmacology: Immunomodulation and Immunotherapy. JAMA
278: 2008-2017
[Abstract]
(1997). Immunopathogenesis of Psoriasis: The Road From Bench to Bedside is a 2-Way Street. Arch Dermatol
133: 781-782
[Abstract]
Grossman, R. M., Chevret, S., Abi-Rached, J., Blanchet, F., Dubertret, L.
(1996). Long-term Safety of Cyclosporine in the Treatment of Psoriasis. Arch Dermatol
132: 623-629
[Abstract]
Ruzicka, T.
(1996). Psoriatic Arthritis: New Types, New Treatments. Arch Dermatol
132: 215-219
[Abstract]
Ellis, C. N., Fradin, M. S., Hamilton, T. A., Voorhees, J. J.
(1995). Duration of Remission During Maintenance Cyclosporine Therapy for Psoriasis: Relationship to Maintenance Dose and Degree of Improvement During Initial Therapy. Arch Dermatol
131: 791-795
[Abstract]
Greaves, M. W., Weinstein, G. D.
(1995). Treatment of Psoriasis. NEJM
332: 581-589
[Full Text]
Feagan, B. G., McDonald, J., Rochon, J., Laupacis, A., Fedorak, R. N., Kinnear, D., Saibil, F., Groll, A., Archambault, A., Gillies, R., Valberg, B., Irvine, E. J., The Canadian Crohn's Relapse Prevention Trial Inve,
(1994). Low-Dose Cyclosporine for the Treatment of Crohn's Disease. NEJM
330: 1846-1851
[Abstract][Full Text]
Griffiths, C. E. M.
(1994). Cutaneous Leukocyte Trafficking and Psoriasis. Arch Dermatol
130: 494-499
[Abstract]
Reitamo, S., Erkko, P., Remitz, A., Lauerma, A. I., Montonen, O., Harjula, K.
(1993). Cyclosporine in the Treatment of Palmoplantar Pustulosis: A Randomized, Double-blind, Placebo-Controlled Study. Arch Dermatol
129: 1273-1279
[Abstract]
Stern, B. J., Schonfeld, S. A., Sewell, C., Krumholz, A., Scott, P., Belendiuk, G.
(1992). The Treatment of Neurosarcoidosis With Cyclosporine. Arch Neurol
49: 1065-1072
[Abstract]
Burns, M. K., Ellis, C. N., Eisen, D., Duell, E., Griffiths, C. E. M., Annesley, T. M., Hamilton, T. A., Birnbaum, J. E., Voorhees, J. J.
(1992). Intralesional Cyclosporine for Psoriasis: Relationship of Dose, Tissue Levels, and Efficacy. Arch Dermatol
128: 786-790
[Abstract]
Kulms, D., Schwarz, T.
(2001). Ultraviolet Radiation Inhibits Interleukin-2-induced Tyrosine Phosphorylation and the Activation of STAT5 in T Lymphocytes. J. Biol. Chem.
276: 12849-12855
[Abstract][Full Text]
